EytanMosheSteinMD

Hematologic Oncology

Physician

Overview of Dr. Stein

Dr. Eytan Stein is an oncologist in New York, NY and is affiliated with Memorial Sloan Kettering Cancer Center. He received his medical degree from McGaw Medical Center of Northwestern University and has been in practice 13 years. He is one of 503 doctors at Memorial Sloan Kettering Cancer Center who specialize in Oncology. He has more than 100 publications and over 500 citings.

Office
530 East 74th Street
New York, NY 10021
Book by Phone+1(231) 680-2314

Education & Training

Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2010 - 2013
McGaw Medical Center of Northwestern UniversityResidency, Internal Medicine, 2007 - 2010
Northwestern University The Feinberg School of MedicineClass of 2007

Certifications & Licensure

FL State Medical License 2021 - Present
NY State Medical License 2010 - 2027
CT State Medical License 2023 - 2025
NJ State Medical License 2018 - 2025
NC State Medical License 2020 - 2022
IL State Medical License 2007 - 2010
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Clinical Trials

A Safety Study of SGN-CD33A in AML Patients Start of enrollment: 2013 Jul 01
Completed
Phase 1
A Phase 2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Myelofibrosis Start of enrollment: 2014 Jul 16
Active, not recruiting
Phase 1, Phase 2
Study of Biomarker-Based Treatment of Acute Myeloid Leukemia Start of enrollment: 2016 Nov 01
Recruiting
Phase 1, Phase 2
Pinometostat and Azacitidine in Treating Patients With Relapsed, Refractory, or Newly Diagnosed Acute Myeloid Leukemia With 11q23 Rearrangement Start of enrollment: 2020 Mar 06
Completed
Phase 1, Phase 2
A Study of BTX-A51 in People With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome Start of enrollment: 2020 Jan 06
Recruiting
Phase 1
FHD-286 as Monotherapy or Combination Therapy in Subjects With Advanced Hematologic Malignancies Start of enrollment: 2021 Jun 14
Recruiting
Phase 1
Tamibarotene Plus Venetoclax/Azacitidine in Participants With Newly Diagnosed AML Start of enrollment: 2021 Aug 26
Recruiting
Phase 2
Roles: Contact, Principal Investigator
Study of CB-5339 in Acute Myeloid Leukemia or Myelodysplastic Syndrome Start of enrollment: 2020 Jun 08
Completed
Phase 1
Roles: Contact, Principal Investigator
A Study of Enasidenib in People With Clonal Cytopenia of Undetermined Significance Start of enrollment: 2021 Oct 06
Recruiting
Phase 1
Roles: Principal Investigator, Contact
A Study of E7820 in People With Bone Marrow (Myeloid) Cancers Start of enrollment: 2021 Aug 13
Active, not recruiting
Phase 2
Roles: Principal Investigator, Contact
A Study to Evaluate Lanraplenib (LANRA) in Combination With Gilteritinib in Participants With FLT3-mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) Start of enrollment: 2022 Aug 05
Terminated
Phase 1, Phase 2
Roles: Contact
A Study of Gilteritinib in Combination With Ivosidenib or Enasidenib in People With Acute Myeloid Leukemia (AML) Start of enrollment: 2023 Jun 26
Recruiting
Phase 1
Roles: Principal Investigator, Contact
A Study of GLB-001 in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher Risk Myelodysplastic Syndromes Start of enrollment: 2024 Jan 11
Recruiting
Phase 1
Roles: Contact
Safety and Clinical Activity of KT-253 in Adult Patients With High Grade Myeloid Malignancies, Acute Lymphocytic Leukemia, Lymphoma, Solid Tumors Start of enrollment: 2023 May 15
Recruiting
Phase 1
Roles: Contact
Expanded Access Program for Revumenib
Available
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

HMA/VEN treatment modifications and associated outcomes in-mutant AML.
Kuo-Kai Chin, Andriy Derkach, Christopher Famulare, Gaurav K Gupta, P Dayand Borge
Leukemia & Lymphoma. 2025-02-01
Phase Ib study of PRT543, an oral protein arginine methyltransferase 5 (PRMT5) inhibitor, in patients with advanced splicing factor-mutant myeloid malignancies.
Jan Philipp Bewersdorf, Xiaoli Mi, Bin Lu, Andrew Kuykendall, David Sallman
Leukemia. 2025-01-24
Defining 2 Biologically and Clinically Distinct Groups in Acute Leukemia with a Mixed Phenotype.
Pallavi Galera, Deepika Dilip, Andriy Derkach, Alexander Chan, Yanming Zhang
Blood. 2025-01-15

Journal Articles

Disrupted Radial and Tibial Microarchitecture in Patients with Monoclonal Gammopathy of Undetermined Significance
E Shane, E M Stein, S Lentzsch, J Fu, Osteoporosis international
Clonal Heterogeneity of Acute Myeloid Leukemia Treated with the IDH2 Inhibitor Enasidenib
Eytan Stein, MD, Nature
Acquired Resistance to IDH Inhibition Through Trans or Cis Dimer-Interface Mutations
Martin S Tallman, Eytan M Stein, Alan H Shih, Maria E Arcila, Andrew M Intlekofer, Craig B Thompson, Mikhail Roshal, Nature
Abnormal Microarchitecture and Stiffness in Postmenopausal Women Using Chronic Inhaled Glucocorticoids
E Dimango, E Shane, E M Stein, Osteoporosis international
Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML
Daniel A Pollyea, Amir T Fathi, Geoffrey L Uy, Robert K Stuart, Mikkael A Sekeres, Courtney D DiNardo, Alice S Mims, Eyal C Attar, Richard M Stone, Hagop M Kantarjian,..., The New England Journal of Medicine
A Phase 1 Trial of Vadastuximab Talirine Combined with Hypomethylating Agents in Patients with CD33 Positive AML
Eytan M Stein, Anand Jillella, Anthony S Stein, Amir T Fathi, Roland B Walter, Jeffrey E Lancet, Tibor J Kovacsovics, Anjali S Advani, Phoenix A Ho, Dale Bixby, Blood
Join now to see all

Abstracts/Posters

Ivosidenib (AG-120) in Patients with IDH1-Mutant Relapsed/Refractory Myelodysplastic Syndrome: Updated Enrollment of a Phase 1 Dose Escalation and Expansion Study
Eytan M. Stein, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Combined Venetoclax and Hypomethylating Agent (HMA) Therapy Induces High Response Rates in Patients with Myelodysplastic Syndrome Including Patients Previously Failing...
Eytan M. Stein, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Newly Diagnosed AML Patient Samples Demonstrate High Degree of Concordance in Identification of Pathogenic Mutations By Next Generation Sequencing (NGS) Performed at E...
Eytan M. Stein, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Bone Marrow Morphologic Findings in Patients Receiving IDH Inhibitor Therapy in Combination with Intensive Induction Chemotherapy: Challenges with Interpretation of th...
Eytan M. Stein, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Molecular Mechanisms Mediating Relapse Following Ivosidenib Monotherapy in Patients with IDH1-Mutant Relapsed or Refractory Acute Myeloid Leukemia
Eytan M. Stein, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Leukemia Cell of Origin Influences p53 Activity and Therapeutic Sensitivity Via an Evi1-Dependent Mechanism
Eytan M. Stein, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
A Phase Ib/II Study of the Histone Methyltransferase Inhibitor Pinometostat in Combination with Azacitidine in Patients with 11q23-Rearranged Acute Myeloid Leukemia
Eytan M. Stein, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Complex Polyclonal Resistance Mechanisms to Ivosidenib Monotherapy in IDH1-Mutant Relapsed or Refractory Acute Myeloid Leukemia Revealed By Single Cell Sequencing Anal...
Eytan M. Stein, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Treatment Patterns and Outcomes in Patients with Myelodysplastic Syndromes Treated with Hypomethylating Agents: A SEER-Medicare Analysis
Eytan M. Stein, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Prevalence of Inherited Cancer Predisposition Mutations in a Cohort of Older AML Patients Enrolled on the Beat AML Master Trial
Eytan M. Stein, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Safety and Efficacy of Combined Ruxolitinib and Thalidomide in Patients with Myelofibrosis: A Phase II Study
Eytan M. Stein, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Precision Medicine Treatment in Older AML: Results of Beat AML Master TrialClinically Relevant Abstract
Eytan M. Stein, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
RAS Mutations Are Independently Associated with Decreased Overall Survival and Event-Free Survival in Patients with AML Receiving Induction Chemotherapy
Eytan M. Stein, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Improved Overall Survival with Enasidenib Compared with Standard of Care Among Patients with Relapsed or Refractory Acute Myeloid Leukemia and IDH2 Mutations: A Propen...
Eytan M. Stein, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
High Rate of IDH1 Mutation Clearance and Measurable Residual Disease Negativity in Patients with IDH1-Mutant Newly Diagnosed Acute Myeloid Leukemia Treated with Ivosid...
Eytan M. Stein, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Enasidenib Plus Azacitidine Significantly Improves Complete Remission and Overall Response Compared with Azacitidine Alone in Patients with Newly Diagnosed Acute Myelo...
Eytan M. Stein, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Join now to see all

Lectures

Use of Molecular Medicine to Assess Pretreatment Prognosis of Myeloid Disorders
ASCO Annual Meeting 2019 - Chicago, IL - 5/31/2019
Clinical Management of Myeloid Malignancies: The Coming of Age of Targeted Therapies
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Adult Clinical Malignant Hematology
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Selinexor, a First-in-Class XPO1 Inhibitor, Is Efficacious and Tolerable in Patients with Myelodysplastic Syndromes Refractory to Hypomethylating Agents
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
AML with Mutations in IDH1 and DNMT3A Exhibits a Distinct Epigenetic Signature with Poorer Overall Survival
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Ivosidenib (AG-120) Induced Durable Remissions and Transfusion Independence in Patients with IDH1-Mutant Relapsed or Refractory Myelodysplastic Syndrome: Results from ...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
A Precision Medicine Heirarchical Classification Developed Using Variant Allele Frequency (VAF) for Treatment of Older Patients (Pts) with Acute Myeloid Leukemia (AML)...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Focus on AML: Clinical Practice Today
60th American Society of Hematology Annual Meeting - 11/30/2018
AGILE: A phase 3, multicenter, randomized, placebo-controlled study of ivosidenib in combination with azacitidine in adult patients with previously untreated acute mye...
2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
Enasidenib for Acute Myeloid Leukemia. FDA Approvals and Their Incorporation into Clinical Practice
2018 ASCO Annual Meeting - Chicago, Illinois - 06/1/2018
Join now to see all

Press Mentions

$Syndax Announces Positive Pivotal Topline Results from Relapsed or Refractory mNPM1 AML Cohort in AUGMENT-101 Trial of Revumenib$
Syndax Announces Positive Pivotal Topline Results from Relapsed or Refractory mNPM1 AML Cohort in AUGMENT-101 Trial of RevumenibNovember 12th, 2024
Nearly a Third of Leukemia Patients Saw Remission After Taking Experimental PillMarch 30th, 2023
Near-Terminal Leukemia Patients in Remission as Experimental Drug Raises HopeMarch 16th, 2023
Join now to see all